Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol + serplulimab + EC chemotherapy in first-line extensive-stage small cell lung cancer
ChiCTR2600125356Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carvedilol, serplulimab, etoposide and carboplatin in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Objective Response Rate (ORR), Disease Control Rate (DCR) and 7 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
carvedilolserplulimabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600125356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125356.